As of June 3, 2020, there were 6,551,389 global COVID-19 cases with 386,196 deaths. Although approximately 98% of patients experience mild disease, 2% experience severe disease often requiring critical care support.^[@CIT0001],[@CIT0002]^

To date, physicians and intensivists treating patients with COVID-19 have limited treatment options in the absence of an effective antiviral agent or vaccine.^[@CIT0003]^ Therapeutic options in the form of convalescent plasma therapy, remdesivir, tocilizumab, and repurposing of various drugs are being explored.^[@CIT0006]^ Recently, a few studies have examined the role of mesenchymal stem cells (MSCs) in critically ill patients with COVID-19. These studies have shown some early promise as therapeutic possibilities for the treatment of severe COVID-19.^[@CIT0011]^

Basic Principles of MSC Therapy {#s1}
===============================

In multiple and mostly regenerative clinical settings, MSCs have been evaluated to either treat or prevent a disease or condition characterized by tissue damage. Regenerative treatment models have so far suggested the following major methods of repair:^[@CIT0015],[@CIT0016]^ anti-inflammatory effect; stem cell homing to damaged networks, with recruitment of other cells; inhibition of apoptosis; and differentiation capability. The molecules and exosomes emitted from stem cells promote tissue healing and regeneration. In addition to the direct effect, stem cells also possess a paracrine function that works by releasing the soluble factors termed *stem cell secretomes.*^[@CIT0017],[@CIT0018]^ This property allows the systemic distribution of the positive immunomodulatory and regenerative effects of MSCs throughout the body, thereby ensuring a systemic effect in addition to local modulation.^[@CIT0018]^

Stem Cell Therapies and Concerns {#s2}
================================

The role of MSCs in regenerative medicine has been explored in the past. Many studies have shown the beneficial effects of MSC-based therapies.^[@CIT0014],[@CIT0016],[@CIT0019]^ Such therapies have been studied in various neurological disorders, endocrinopathies, and bone and cartilage diseases. Contrary to these results, some studies have showed that MSCs may promote cancer pathogenesis.^[@CIT0020],[@CIT0021]^ Therefore, the role of MSCs in regenerative medicine and their therapeutic potential needs more study and clarification.^[@CIT0022]^ There is thus a constant effort from research bodies and other agencies such as the U.S. Food and Drug Administration (FDA), the International Society for Cellular Therapy, and the International Society for Stem Cell Research to actively monitor stem cell clinic industries across the globe to minimize unapproved and unproven cell-based therapies.^[@CIT0023],[@CIT0024]^ With regard to the current pandemic, the main challenge is the novelty of the disease, its unfamiliar pathophysiology, and the lack of an anti-SARS-CoV-2 antiviral agent or vaccine. Realizing the pandemic as a time-sensitive matter, the FDA has been relatively liberal in clearing pathways to study MSCs and natural killer (NK) cells for their potential immune activity in response to COVID-19.^[@CIT0025],[@CIT0026]^

Rationale of Using MSCs in COVID-19 {#s3}
===================================

Research has shown that MSCs have specific cytokines that drive immunomodulation, which may be useful against SARS-CoV-2.^[@CIT0027]^ The available literature so far suggests that the hallmark of SARS-CoV-2 infection is a cytokine-induced storm. SARS-CoV-2 induces an acute release of cytokines such as granulocyte colony-stimulating factor, IP10, Monocyte Chemoattractant Protein-1, interleukin (IL)-2/6/7, and tumor necrosis factor (TNF) in large amounts.^[@CIT0028],[@CIT0029]^ These cytokines lead to increased vasculature permeability, pulmonary edema, vascular congestion, and impairment of air exchange across the membranes, and in severe cases they may lead to acute respiratory distress syndrome (ARDS) and death.

Recently, Huang et al^[@CIT0030]^ studied the cytokine profile of 41 patients with COVID-19. They found higher plasma levels of proinflammatory cytokines in patients in the intensive care unit (ICU) than in patients who were not. Chen, Wu, et al^[@CIT0031]^ found markedly lower absolute numbers of T lymphocytes, CD4+ T cells, and CD8+ T cells in patients with severe cases.^[@CIT0031]^ The patients with high cytokine levels, lower CD4+ T cells, and lower CD8+ T cells became more sick, required ICU care, and had a higher likelihood of developing ARDS.

Current efforts with MSC therapeutics are focusing on the capability of MSCs to abort or minimize this cytokine storm, thereby reducing lung damage and promoting the restoration of tissue function through their inherent reparative properties.^[@CIT0032]^ The MSCs express angiotensin-converting enzyme 2 (ACE-2) and transmembrane protease serine 2 (TMPRSS2) cells and have the potential to induce mature dendritic cells (DCs) to novel Jagged-2 dependent regulatory DCs that possess an immunosuppressive capacity to generate specific immune tolerance and diminish Th2-type inflammation.^[@CIT0033],[@CIT0034]^ The MSCs also help in the preferable differentiation of human CD34+ cells to regulatory DCs over classical DCs.^[@CIT0035]^ Based on these immunomodulatory functions, Leng et al^[@CIT0011]^ found MSC infusion beneficial in their patients with COVID-19. Similarly, Zhao^[@CIT0036]^ also suggested that MSCs could help patients who are critically ill with COVID-19.

Biological Characteristics of MSCs and Identification of the Best Stem Cell Source {#s4}
==================================================================================

Stem cells derived from various tissues in the body are being evaluated for therapies in numerous degenerative disorders.^[@CIT0016],[@CIT0037]^ The common stem cells used in clinical practice originate from bone marrow (BM), adipose tissue (AT), amnion, the umbilical cord (UC), dental pulp, menstrual blood, the buccal fat pad, and fetal liver.^[@CIT0037]^ The MSCs hold much promise to change the dynamics of incurable diseases for many reasons: (i) easy accessibility, (ii) multipotency, (iii) ease of expansion to required clinical volume, (iv) storage potential for repetitive therapeutic usage, (v) immune evasive property indicating a minimal chance of rejection with allogeneic MSCs, and (vi) easy route of administration (via intravenous \[IV\]).

For patients with COVID-19, among the various stem cells, UC mesenchymal stem cells (UC-MSCs) have recently gained more attention because of their ready availability, compatibility, potency, and plasticity:^[@CIT0019],[@CIT0038]^

1.  When compared with BM, UC harvests have a higher concentration of stem cells.

2.  The UC-MSCs have a faster doubling time.

3.  A higher proliferation rate of UC-MSCs allows for a scalable expansion that may benefit a larger population of critically ill patients.

4.  The harvesting tissue for UC-MSCs is a byproduct during delivery and does not require any invasive procedure unlike BM stem cell extraction.

5.  The UC-MSCs have the advantage of being immune tolerant because of low expression of major histocompatibility complex (MHC) class I and no expression of MHC class II. These characteristics allow the use of even allogeneic MSCs.

Similarly, another potential source of MSCs with an advantage over other harvesting sites is AT. Using AT-derived MSCs has the following benefits:^[@CIT0038],[@CIT0039]^

1.  Easily accessible site for extraction that poses minimum discomfort to the donor.

2.  Comparatively easy to isolate MSCs from the harvested AT.

3.  Comparatively, a higher fraction of MSCs can be extracted from harvested AT compared with BM.

4.  Comparatively, a higher success rate of isolating MSCs from AT than UC.

Reviving COVID-19-Induced Lung Damage via MSCs {#s5}
==============================================

Studies on animal models have shown that pneumocyte type II cells support coronavirus replication better than pneumocyte type I cells and alveolar macrophages.^[@CIT0042],[@CIT0043]^ In addition, postmortem histopathology examination of lung tissue from patients with COVID-19 has shown significant lung damage with evidence of diffuse alveolar damage, type II pneumocyte hyperplasia, and intra-alveolar fibrinous exudates.^[@CIT0044]^ Recent studies have provided ample evidence that stem cells promote lung tissue healing and regeneration by differentiating to pulmonary epithelial cells. Once injected intravenously, a significant amount of MSCs accumulate in the lung and exhibit an immunomodulatory effect, thereby protecting the alveolar epithelial cells, restoring the pulmonary alveolar niche, preventing fibrosis, and improving overall pulmonary function.^[@CIT0045],[@CIT0046]^ This phenomenon may benefit critically ill patients with COVID-19 and help them recover from ARDS, pulmonary edema, and diffuse alveolar damage.

Clinical Use of MSCs in COVID-19: Paucity of Data {#s6}
=================================================

The COVID-19 pandemic is evolving, and we are still in the learning phase. There is a lack of impactful data on MSC therapeutics for COVID-19. Physicians can extrapolate the potential clinical benefits of MSCs in COVID-19 pneumonia based on studies from previous viral outbreaks with positive outcomes.^[@CIT0047]^ Chen et al infused MSCs extracted from allogeneic menstrual blood from healthy female donors into 17 patients with H7N9-induced ARDS. They found a significant mortality benefit in the MSC-infused arm (17.6% died) as compared with the control arm (54.5% died). The major limitations of the study were the small sample size, high attrition rate, and not-ideal comparison sample because patients were receiving other drugs as well.

Because H7N9 and SARS-CoV-2 share similar complications---ARDS, hypoxic respiratory failure, severe inflammation, overt immune response, and multiorgan dysfunction syndrome---MSCs therapy may be beneficial for patients with COVID-19 pneumonia as well.^[@CIT0027],[@CIT0028]^ A recent meta-analysis on MSC use in ARDS (study period 1990 to March 31, 2020)^[@CIT0007]^ showed an improvement in radiographic shadows, pulmonary function, and biochemical marker levels. This meta-analysis also showed a mortality benefit with the use of MSCs but not to a significant level.

With regard to COVID-19, Leng et al^[@CIT0011]^ recently used BM-derived MSCs intravenously in 7 patients with COVID-19 (1 critically severe illness, 4 severe illnesses, and 2 common illnesses). Significant clinical benefit was noted in all patients with symptomatic improvement and reduced oxygen requirement after 2 to 4 days of MSC transplantation. Mass cytometry and cytokine analysis of the patients' peripheral blood also showed disappearance of overactivated T cells and NK cells, an increase in anti-inflammatory cytokines like IL-10, and a decrease in proinflammatory cytokines like TNF-alpha. However, the small sample size, the lack of a control arm, patients who were also receiving other drugs, and a patient cohort with only 1 patient with critical serious illness are possible limitations to consider before analyzing the results.

The above-discussed studies regarding the use of MSCs in COVID-19 have provided a much-needed clinical platform for further research on MSCs in COVID-19 and other viral disorders. Therapy using MSC in high-risk populations including pregnant women, patients with human immunodeficiency virus, patients with malignancies, and transplant recipients would need further refinement before being executed.^[@CIT0048]^ In addition, it is too early to suggest that MSCs are safe to use in patients with COVID-19 and requires further confirmation.^[@CIT0053],[@CIT0054]^

Current Literature on Ongoing Trials of MSCs for COVID-19 {#s7}
=========================================================

Recently, clinical trials studying various aspects of MSC use in COVID-19 are underway in several clinical phases (**[Figure 1](#F1){ref-type="fig"}**). China and the United States are the 2 leading countries studying cell-based therapy--related clinical trials, from which some reports have been published as well (**[Table 1](#T1){ref-type="table"}**).^[@CIT0055],[@CIT0056]^ As of April 21, 2020, 40 clinical trials were active across the globe (<http://www.chictr.org.cn/index.aspx> and <https://clinicaltrials.gov/>). Zhongnan Hospital in China and its collaborator, Tuohua Biological Technology Co. Ltd., are studying UC-MSC treatment (IV on day 1, day 3, day 5, and day 7) in patients with serious and critical pneumonia. The primary outcome is to study the improvement in oxygenation index on day 14 after enrollment (NCT04269525). Similarly, Renmin Hospital of Wuhan University is planning to evaluate the safety and efficacy of allogeneic human dental pulp MSCs in severe pneumonia caused by COVID-19 (ChiCTR2000031319). Elsewhere, scientists from other countries including the United Kingdom, Brazil, Jordan, and France are conducting similar MSC therapy clinical trials for COVID-19.

![Number of studies currently enrolled regarding MSCs in COVID-19 by country (as of April 22, 2020).](lmaa049f0001){#F1}
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List of Registered Cell-Based Clinical Trials for Treating COVID-19 Worldwide

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  ClinicalTrials.gov Identifier   Title                                                                                                                                                                                                                                         Study Characteristics                                      Primary Outcome Measures                                                                                                                     Responsible Party
  ------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------
  United States                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

  NCT04299152                     Clinical Application of Stem Cell Educator Therapy for the Treatment of Viral Inflammation Caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)                                                                             ---Interventional study\                                   Determine the number of patients with COVID-19 who were unable to complete SCE therapy (time frame: 4 weeks)                                 Tianhe Stem Cell Biotechnologies Inc., China
                                                                                                                                                                                                                                                                                ---Estimated participants: 20\                                                                                                                                                                          
                                                                                                                                                                                                                                                                                ---Study design: parallel                                                                                                                                                                               

  NCT04348435                     A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Allogeneic Mesenchymal Stem Cell Therapy (HB-adMSCs) to Provide Protection Against COVID-19                            ---Interventional study\                                   ---Incidence of hospitalization for COVID-19 (time frame: week 0 through week 26 \[end of study\])\                                          Hope Biosciences Stem Cell Research Foundation,\
                                                                                                                                                                                                                                                                                ---Estimated participants: 100\                            ---Incidence of symptoms associated with COVID-19 (time frame: week 0 through week 26 \[end of study\])                                      Sugar Land, TX
                                                                                                                                                                                                                                                                                ---Study design: parallel                                                                                                                                                                               

  NCT04355728                     Umbilical Cord-derived Mesenchymal Stem Cells for COVID-19 Patients with Acute Respiratory Distress Syndrome (ARDS)                                                                                                                           ---Interventional study\                                   ---Incidence of prespecified infusion-associated AEs (time frame: day 5)\                                                                    Diabetes Research Institute, University of Miami Miller School of Medicine,\
                                                                                                                                                                                                                                                                                ---Estimated participants: 12\                             ---Incidence of SAEs (time frame: 90 days)                                                                                                   Miami, FL
                                                                                                                                                                                                                                                                                ---Study design: parallel                                                                                                                                                                               

  NCT04345601                     Single Donor Banked Bone Marrow Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure: A Pilot Study                                                                                                    ---Interventional study\                                   ---Incidence of unexpected AEs (time frame: 28 days post---cell infusion)\                                                                   Houston Methodist Hospital,\
                                                                                                                                                                                                                                                                                ---Estimated participants: 30\                             ---Improved oxygen saturations ≥ 93% (time frame: within 7 days of cell infusion)                                                            Houston, TX
                                                                                                                                                                                                                                                                                ---Intervention model: single group                                                                                                                                                                     

  China                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  ChiCTR2000031319                Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe Pneumonia of COVID-19: a Single-center, Prospective, Randomised Clinical Trial                                                               ---Interventional study\                                   ...                                                                                                                                          Center for Regenerative Medicine, Renmin Hospital of Wuhan University, China
                                                                                                                                                                                                                                                                                ---Estimated participants: 20\                                                                                                                                                                          
                                                                                                                                                                                                                                                                                ---Study design: parallel                                                                                                                                                                               

  ChiCTR2000031735                Clinical study for natural killer (NK) cells from umbilical cord blood in the treatment of viral pneumonia include novel coronavirus pneumonia (COVID-19)                                                                                     ---Interventional study\                                   Monitoring of AEs within 24 hours after infusion (including infusion-related events and SAEs associated with nonprimary disease)             Huzhou Central Hospital, Zhejiang, China
                                                                                                                                                                                                                                                                                ---Estimated participants: 20\                                                                                                                                                                          
                                                                                                                                                                                                                                                                                ---Study design: parallel                                                                                                                                                                               

  ChiCTR2000031139                Safety and Effectiveness of Human embryonic stem cell-derived M cells (CAStem) for Pulmonary Fibrosis Correlated with novel coronavirus pneumonia (COVID-19)                                                                                  ---Interventional study\                                   ---Pulmonary function evaluation\                                                                                                            Wuhan Jinyintan Hospital (Wuhan Infectious Diseases Hospital), Wuhan, Hubei, China
                                                                                                                                                                                                                                                                                ---Estimated participants: 20\                             ---Changes in blood gas analysis\                                                                                                            
                                                                                                                                                                                                                                                                                ---Study design: sequential                                ---Evaluation of activity\                                                                                                                   
                                                                                                                                                                                                                                                                                                                                           ---Evaluation of dyspnea                                                                                                                     

  ChiCTR2000030509                Clinical Study of NK Cells in the Treatment of Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                                         ---Interventional study\                                   Time and rate of novel coronavirus become negative                                                                                           The First Hospital of Harbin Medical University, Harbin, Heilongjiang, China
                                                                                                                                                                                                                                                                                ---Estimated participants: 40\                                                                                                                                                                          
                                                                                                                                                                                                                                                                                ---Study design: parallel                                                                                                                                                                               

  ChiCTR2000030329                Clinical trial for umbilical cord blood CIK and NK cells in the treatment of mild and general patients infected with novel coronavirus pneumonia (COVID-19)                                                                                   ---Interventional study\                                   ---Status of immune function\                                                                                                                The Second Affiliated Hospital of Xi'an Medical University, Xi'an, Shaanxi, China
                                                                                                                                                                                                                                                                                ---Estimated participants: 90\                             ---Nucleic acid test is negative\                                                                                                            
                                                                                                                                                                                                                                                                                ---Study design: parallel                                  ---Length of stay in hospital                                                                                                                

  ChiCTR2000030224                Clinical study of mesenchymal stem cells in treating severe novel coronavirus pneumonia (COVID-19)                                                                                                                                            ---Interventional study\                                   ---Inflammatory biomarkers\                                                                                                                  Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
                                                                                                                                                                                                                                                                                ---Estimated participants: 32\                             ---Blood routine\                                                                                                                            
                                                                                                                                                                                                                                                                                ---Study design: parallel                                  ---Temperature\                                                                                                                              
                                                                                                                                                                                                                                                                                                                                           ---Lesions of lung seen in CT scan                                                                                                           

  ChiCTR2000030173                Key techniques of umbilical cord mesenchymal stem cells for the treatment of novel coronavirus pneumonia (COVID-19) and clinical application demonstration                                                                                    ---Interventional study\                                   ---Pulmonary function\                                                                                                                       Nanhua Hospital, affiliated with Nanhua University, Hengyang, Hu'nan, China
                                                                                                                                                                                                                                                                                ---Estimated participants: 60\                             ---Novel coronavirus pneumonic nucleic acid test                                                                                             
                                                                                                                                                                                                                                                                                ---Study design: parallel                                                                                                                                                                               

  ChiCTR2000030088                Umbilical cord Wharton's Jelly derived mesenchymal stem cells in the treatment of severe novel coronavirus pneumonia (COVID-19)                                                                                                               ---Interventional study\                                   ---Nucleic acid test for novel coronavirus is negative\                                                                                      The Sixth Medical Center of PLA General Hospital, Beijing, China
                                                                                                                                                                                                                                                                                ---Estimated participants: 40\                             ---CT scan of ground glass shadow disappeared                                                                                                
                                                                                                                                                                                                                                                                                ---Study design: parallel                                                                                                                                                                               

  ChiCTR2000030020                The clinical application and basic research related to mesenchymal stem cells to treat novel coronavirus pneumonia (COVID-19)                                                                                                                 ---Interventional study\                                   ---Coronavirus nucleic acid markers have negative rate\                                                                                      Second Hospital of University of South China, Hengyang, China
                                                                                                                                                                                                                                                                                ---Estimated participants: 40\                             ---Inflammation (per chest CT)\                                                                                                              
                                                                                                                                                                                                                                                                                ---Study design: sequential                                ---Symptoms improved after 4 treatments                                                                                                      

  ChiCTR2000029816                Clinical Study of Cord Blood Mesenchymal Stem Cells in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19)                                                                                                                          ---Interventional study\                                   Time to disease recovery                                                                                                                     Guangzhou Reborn Health Management Consultation Co, Ltd, Guangzhou, Guangdong, China
                                                                                                                                                                                                                                                                                ---Estimated participants: 60\                                                                                                                                                                          
                                                                                                                                                                                                                                                                                ---Study design: parallel                                                                                                                                                                               

  ChiCTR2000029812                Clinical Study for Umbilical Cord Blood Mononuclear Cells in the Treatment of Acute Novel Coronavirus Pneumonia (NCP)                                                                                                                         ---Interventional study\                                   Time to disease recovery                                                                                                                     Guangzhou Reborn Health Management Consultation Co, Ltd, Guangzhou, Guangdong, China
                                                                                                                                                                                                                                                                                ---Estimated participants: 60\                                                                                                                                                                          
                                                                                                                                                                                                                                                                                ---Study design: parallel                                                                                                                                                                               

  ChiCTR2000029606                Clinical Study for Human Menstrual Blood-derived Stem Cells in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19)                                                                                                                  ---Interventional study\                                   Mortality in patients                                                                                                                        The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
                                                                                                                                                                                                                                                                                ---Estimated participants: 63\                                                                                                                                                                          
                                                                                                                                                                                                                                                                                ---Study design: parallel                                                                                                                                                                               

  ChiCTR2000029580                Severe novel coronavirus pneumonia (COVID-19) patients treated with ruxolitinib in combination with mesenchymal stem cells: a prospective, single blind, randomized controlled clinical trial                                                 ---Interventional study\                                   Safety                                                                                                                                       Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
                                                                                                                                                                                                                                                                                ---Estimated participants: 70\                                                                                                                                                                          
                                                                                                                                                                                                                                                                                ---Study design: parallel                                                                                                                                                                               

  ChiCTR2000029572                Safety and efficacy of umbilical cord blood mononuclear cells in the treatment of severe and critically novel coronavirus pneumonia (COVID-19): a randomized controlled clinical trial                                                        ---Interventionalstudy\                                    PSI                                                                                                                                          Xiangyang First People's Hospital, Xiangyang, Hubei, China
                                                                                                                                                                                                                                                                                ---Estimated participants: 30\                                                                                                                                                                          
                                                                                                                                                                                                                                                                                ---Study design: parallel                                                                                                                                                                               

  ChiCTR2000029569                Safety and efficacy of umbilical cord blood mononuclear cells conditioned medium in the treatment of severe and critically novel coronavirus pneumonia (COVID-19): a randomized controlled trial                                              ---Interventional study\                                   PSI                                                                                                                                          Xiangyang First People's Hospital,\
                                                                                                                                                                                                                                                                                ---Estimated participants: 30\                                                                                                                                                                          Xiangyang, Hubei, China
                                                                                                                                                                                                                                                                                ---Study design: parallel                                                                                                                                                                               

  CTR2000030116                   Safety and effectiveness of human umbilical cord mesenchymal stem cells in the treatment of acute respiratory distress syndrome of severe novel coronavirus pneumonia (COVID-19)                                                              Interventional study\                                      Time to leave ventilator on day 28 after receiving MSC infusion                                                                              The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
                                                                                                                                                                                                                                                                                ---Estimated participants: 16\                                                                                                                                                                          
                                                                                                                                                                                                                                                                                ---Study design:\                                                                                                                                                                                       
                                                                                                                                                                                                                                                                                dose comparison                                                                                                                                                                                         

  ChiCTR2000030484                HUMSCs and Exosomes Treating Patients with Lung Injury following Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                       ---Interventional study\                                   ---PaO~2~/FiO~2~ or respiratory rate (without oxygen)\                                                                                       Hubei Shiyan Taihe Hospital, Shiyan, Hubei, China
                                                                                                                                                                                                                                                                                ---Estimated participants: 90\                             ---Frequency of respiratory exacerbation\                                                                                                    
                                                                                                                                                                                                                                                                                ---Study design: parallel                                  ---Observe physical signs and symptoms and record clinical recovery time\                                                                    
                                                                                                                                                                                                                                                                                                                                           ---Number and range of lesions indicated by CT and X-ray of lung\                                                                            
                                                                                                                                                                                                                                                                                                                                           ---Time for cough to become mild or absent\                                                                                                  
                                                                                                                                                                                                                                                                                                                                           ---Time for dyspnea to become mild or no dyspnea\                                                                                            
                                                                                                                                                                                                                                                                                                                                           ---Frequency of oxygen inhalation or noninvasive ventilation, frequency of mechanical ventilation\                                           
                                                                                                                                                                                                                                                                                                                                           ---Inflammatory cytokines (eg, CRP/PCT/SAA)\                                                                                                 
                                                                                                                                                                                                                                                                                                                                           ---Frequency of SAE                                                                                                                          

  ChiCTR2000030866                Open-label, observational study of human umbilical cord derived mesenchymal stem cells in the treatment of severe and critical COVID-19.                                                                                                      Observational study\                                       -Oxygenation index (PaO~2~/ FiO~2~)\                                                                                                         Changsha First Hospital, Changsha, Hu'nan, China
                                                                                                                                                                                                                                                                                ---Estimated participants: 30\                             ---Conversion rate from serious to critical patients\                                                                                        
                                                                                                                                                                                                                                                                                Study design: single arm                                   ---Conversion rate and conversion time from critical to serious patients\                                                                    
                                                                                                                                                                                                                                                                                                                                           ---Mortality in serious and critical patients                                                                                                

  ChiCTR2000030835                Clinical study on the efficacy of Mesenchymal stem cells (MSC) in the treatment of severe novel coronavirus pneumonia (COVID-19)                                                                                                              ---Interventional study\                                   NA                                                                                                                                           The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, He'nan, China
                                                                                                                                                                                                                                                                                ---Estimated participants: 20\                                                                                                                                                                          
                                                                                                                                                                                                                                                                                ---Study design:single arm                                                                                                                                                                              

  ChiCTR2000030138                Clinical Trial for Human Mesenchymal Stem Cells in the Treatment of Severe Novel Coronavirus Pneumonia (COVID-19)                                                                                                                             ---Interventional study\                                   Clinical index                                                                                                                               Chinese PLA General Hospital, Haidian Distract, Beijing, China
                                                                                                                                                                                                                                                                                ---Estimated participants: 60\                                                                                                                                                                          
                                                                                                                                                                                                                                                                                ---Study design: parallel                                                                                                                                                                               

  NCT04302519                     Clinical Study of Novel Coronavirus Induced Severe Pneumonia Treated by Dental Pulp Mesenchymal Stem Cells                                                                                                                                    ---Interventional study\                                   Disappear time of ground-glass shadow in lungs (time frame: 14 days)                                                                         CAR-T (Shanghai) Biotechnology Co, Ltd, Shanghai, China
                                                                                                                                                                                                                                                                                ---Estimated participants: 24 Study design: single group                                                                                                                                                

  NCT04288102                     Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Human Mesenchymal Stem Cells in Combination with Standard Therapy in the Treatment of COVID-19 Patients With Severe Convalescence       ---Interventional study\                                   Size of lesion area and severity of pulmonary fibrosis by chest CT (time frame: at baseline, day 6, day 10, day 14, day 28, day 90\]         Maternal and Child Hospital of Hubei Province,\
                                                                                                                                                                                                                                                                                ---Estimated participants: 90\                                                                                                                                                                          Wuhan, Hubei, China, and\
                                                                                                                                                                                                                                                                                ---Study design: parallel                                                                                                                                                                               Wuhan Huoshenshan Hospital,\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Wuhan, Hubei, China

  NCT04273646                     Clinical Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Severe COVID-19                                                                                                                                             ---Interventional study\                                   ---Pneumonia severity index (time frame: from baseline to 12 weeks after treatment)\                                                         Union Hospital, Tongji Medical College, Huazhong University of Science and Technology,\
                                                                                                                                                                                                                                                                                ---Estimated participants: 48\                             ---Oxygenation index (PaO~2~/FiO~2~; time frame: from baseline to 12 weeks after treatment)                                                  Wuhan, Hubei, China
                                                                                                                                                                                                                                                                                ---Study design: parallel                                                                                                                                                                               

  NCT04252118                     Safety and Efficiency of Mesenchymal Stem Cell in Treating Pneumonia Patients Infected With COVID-19                                                                                                                                          ---Interventional study\                                   ---Size of lesion area by chest radiograph or CT (time frame: at baseline, day 3, day 6, day 10, day 14, day 21, day 28)\                    Beijing 302 Military Hospital of China,\
                                                                                                                                                                                                                                                                                ---Estimated participants: 20\                             ---Side effects in MSC treatment group (time frame: at baseline, day 3, day 6, day 10, day 14, day 21, day 28, day 90, day 180)              Beijing, China
                                                                                                                                                                                                                                                                                ---Study design: parallel                                                                                                                                                                               

  NCT04269525                     Clinical Research Regarding the Availability and Safety of UC-MSCs Treatment for Serious Pneumonia and Critical Pneumonia Caused by the 2019-nCOV Infection                                                                                   ---Interventional study\                                   Oxygenation index (time frame: on day 14 after enrollment)                                                                                   Zhongnan Hospital, Wuhan, Hubei, China
                                                                                                                                                                                                                                                                                ---Estimated participants: 10\                                                                                                                                                                          
                                                                                                                                                                                                                                                                                ---Intervention model: single group                                                                                                                                                                     

  NCT04276987                     A Pilot Clinical Study on Aerosol Inhalation of the Exosomes Derived From Allogenic Adipose Mesenchymal Stem Cells in the Treatment of Severe Patients With Novel Coronavirus Pneumonia                                                       ---Interventional study\                                   ---Time to clinical improvement (time frame: up to 28 days)\                                                                                 Ruijin Hospital, Wuhan, China
                                                                                                                                                                                                                                                                                ---Estimated participants: 30\                             ---AE and SAE (time frame: up to 28 days)                                                                                                    
                                                                                                                                                                                                                                                                                ---Intervention model: single group                                                                                                                                                                     

  NCT04346368                     Safety and Efficacy of Intravenous Infusion of Bone Marrow-Derived Mesenchymal Stem Cells in Severe Patients with Coronavirus Disease 2019 (COVID-19): A Phase 1/2 Randomized Controlled Trial                                                ---Interventional study\                                   ---AEs in BM-MSC treatment group (time Frame: baseline--6 months)\                                                                           Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University,\
                                                                                                                                                                                                                                                                                ---Estimated participants: 20\                             ---Changes in oxygenation index (PaO~2~/FiO~2~; time frame: baseline, 6hours, day 1, day 3, week 1, week 2, week 4, month 6)                 Guangzhou, Guangdong, China
                                                                                                                                                                                                                                                                                ---Intervention model: Single group                                                                                                                                                                     

  NCT04339660                     Clinical Research of Human Mesenchymal Stem Cells in the Treatment of COVID-19 Pneumonia                                                                                                                                                      ---Interventional study\                                   ---Observe immune function (TNF-α, IL-1β, IL-6, TGF-β, IL-8, PCT, CRP; time frame: within 4 weeks)\                                          Puren Hospital, affiliated with Wuhan University of Science and Technology,\
                                                                                                                                                                                                                                                                                ---Estimated participants: 30\                             ---Monitor blood oxygen saturation (time frame: within 4 weeks)                                                                              Wuhan, Hubei, China
                                                                                                                                                                                                                                                                                ---Study design: parallel                                                                                                                                                                               

  NCT04331613                     Safety and Efficacy Study of Human Embryonic Stem Cells Derived M Cells (CAStem) for the Treatment of Severe COVID-19 Associated With or Without Acute Respiratory Distress Syndrome (ARDS)                                                   ---Interventional study\                                   ---AE and SAE (time frame: within 28 days after treatment)\                                                                                  Beijing YouAn Hospital, Capital Medical University\
                                                                                                                                                                                                                                                                                ---Estimated participants: 09\                             ---Changes in lung imaging examinations (time frame: within 28 days after treatment)                                                         Beijing, Beijing, China,
                                                                                                                                                                                                                                                                                ---Study design: single group                                                                                                                                                                           

  Brazil                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  NCT04315987                     Exploratory Clinical Study to Assess the Efficacy of NestCell Mesenchymal Stem Cell to Treat Patients with Severe COVID-19 Pneumonia                                                                                                          ---Interventional study\                                   Change in clinical condition (time frame: 10 days)                                                                                           Hospital Vera Cruz\
                                                                                                                                                                                                                                                                                ---Estimated participants :66\                                                                                                                                                                          Campina Grande, São Paulo, Brazil
                                                                                                                                                                                                                                                                                ---Study design: single group                                                                                                                                                                           

  Jordan                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  NCT04313322                     Treatment of COVID-19 Patients Using Wharton's Jelly-Mesenchymal Stem Cells                                                                                                                                                                   ---Interventional study\                                   ---Improvement of clinical symptoms (time frame: 3 weeks)\                                                                                   Stem Cells Arabia,\
                                                                                                                                                                                                                                                                                ---Estimated participants: 5\                              ---AEs measured by chest radiograph/CT scan (time frame: 3 weeks)\                                                                           Amman, Jordan
                                                                                                                                                                                                                                                                                ---Intervention model: single group                        ---RT-PCR results of viral RNA turning negative (time frame: 3 weeks)\                                                                       

  France                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  NCT04333368                     Cell Therapy Using Umbilical Cord-derived Mesenchymal Stromal Cells in SARS-CoV-2-related ARDS                                                                                                                                                ---Interventional study\                                   Respiratory efficacy evaluated by increase in PaO~2~/FiO*2* ratio from baseline to day 7 in experimental group compared with placebo group   Hôpital Pitié-Salpêtrière---APHP,\
                                                                                                                                                                                                                                                                                ---Estimated participants: 60\                                                                                                                                                                          Paris, France, and\
                                                                                                                                                                                                                                                                                ---Intervention model: single group                                                                                                                                                                     Hôpital Européen Georges Pompidou---APHP,\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Paris, France

  United Kingdom                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  NCT04349540                     A Prospective Non-Interventional Study to Evaluate the Role of Immune and Inflammatory Response in Recipients of Allogeneic Haematopoietic Stem Cell Transplantation (SCT) Affected by Severe COVID19 Infection                               ---Observational study\                                    ...                                                                                                                                          Great Ormond Street Hospital, NHS Foundation Trust,\
                                                                                                                                                                                                                                                                                ---Estimated participants: 40\                                                                                                                                                                          London, United Kingdom
                                                                                                                                                                                                                                                                                ---Intervention model: case-only                                                                                                                                                                        

  NCT03042143                     Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration (REALIST): An Open Label Dose Escalation Phase 1 Trial Followed by a Randomized, Double-blind, Placebo-controlled Phase 2 Trial (COVID-19)                       ---Interventional study\                                   ---Oxygenation index (time frame: day 7)\                                                                                                    Belfast Health and Social Care Trust, Royal Hospitals\
                                                                                                                                                                                                                                                                                ---Estimated participants: 75\                             ---Incidence of SAEs (time frame: 28 days)                                                                                                   Belfast, Northern Ireland, United Kingdom
                                                                                                                                                                                                                                                                                ---Study design: parallel                                                                                                                                                                               

  Spain                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  NCT04348461                     Two-treatment, Randomized, Controlled, Multicenter Clinical Trial to Assess the Safety and Efficacy of Intravenous Administration of Expanded Allogeneic Adipose Tissue Adult Mesenchymal Stromal Cells in Critically Ill Patients COVID-19   ---Interventional study\                                   ---Efficacy of administration of allogeneic MSCs derived from AT assessed by survival rate (time frame: 28 days)\                            Instituto de Investigación, Sanitaria de la Fundación Jiménez Díaz, Madrid, Spain
                                                                                                                                                                                                                                                                                ---Estimated participants: 100\                            ---Safety of administration of allogeneic MSCs derived from AT assessed by AE rate (time frame: 6 months)                                    
                                                                                                                                                                                                                                                                                ---Study design: parallel                                                                                                                                                                               

  Denmark                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  NCT04341610                     Allogeneic Adipose Tissue Derived Mesenchymal Stromal Cell Therapy for Treating Patients with Severe Respiratory COVID-19. A Danish, Double-blind, Randomized Placebo-controlled Study                                                        ---Interventional study\                                   Changes in clinical critical treatment index (time frame: day 7 from randomization)                                                          Department of Cardiology, The Heart Centre, University Hospital Rigshospitalet,\
                                                                                                                                                                                                                                                                                ---Estimated participants: 40\                                                                                                                                                                          Copenhagen, Denmark
                                                                                                                                                                                                                                                                                ---Study design: parallel                                                                                                                                                                               
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

SCE, stem cell educator; AE, adverse event; SAE, serious adverse event; CT, computed tomography; PSI, patient safety indicators; MSCs, mesenchymal stem cells; PaO2, partial pressure of oxygen; FiO2, fraction of inspired oxygen; PCT, procalcitonin; SAA, serum amyloid A; CRP, C-reactive protein; BM-MSC, bone marrow mesenchymal stem cells; RT-PCR, real-time polymerase chain reaction; AT, adipose tissue

Side Effects and Concerns Over Practical Usability During COVID-19 Pandemic {#s8}
===========================================================================

To prove MSC therapy successful, in addition to evaluating its efficacy it is equally important to assess other practical aspects of community use and accessibility.^[@CIT0057],[@CIT0058]^ With regard to MSCs in COVID-19, although the experience so far has been encouraging, the key barriers still include the following:^[@CIT0059]^

1.  Data to date are preliminary and based on compassionate use of MSCs, with final results from clinical trials still pending.

2.  The downstream effects of MSCs on the lungs are unclear and unknown. For example, we lack an understanding of MSC impact on the expression of ACE-2 and TMPRSS2, which are known facilitators of viral entry into cells and subsequent replication (**[Figure 2](#F2){ref-type="fig"}**).

3.  Similarly, there is a differential expression of ACE-2 receptors in various organ systems. It would be noteworthy to determine whether there would be a difference in the recovery/response of different organs upon MSC infusion.

4.  There is concern over the commercialization and subsequent abuse of unproven cell-based therapies by unauthorized stem cell clinics.

5.  Therapy with MSCs is not a readily available resource, especially in developing countries.

6.  High cost, insurance hurdles, and no standardized treatment protocol are issues of concern. The cost of MSC therapy is extremely variable (between \$5000 and \$50,000) and depends on the type of stem cells, laboratory location (for extraction), patient location (for infusion), and proliferation character of stem cells. To add to the complexity of the situation, in the United States, Medicare does not cover MSC therapy.

7.  In addition, MSC therapy is technically complex, requiring highly specialized staff and equipment.

8.  Scalability because of these technical challenges may lead to a high discrepancy in the supply-demand chain.

9.  There could be immediate adverse effects from MSC infusion; transfusion reactions such as allergies, anaphylaxis, serum sickness, delayed hypersensitivity reactions, and secondary bacteremia. On a positive note, Leng et al^[@CIT0011]^ did not note any acute infusion-related issues, allergic reactions, or delayed hypersensitivity or secondary infections in their cohort of patients. Researchers have found that MSCs are ACE-2 negative and TMPRSS2 negative and are thereby unlikely to become infected by SARS-CoV-2.

![Pictorial description of the source of stem cells, and impact of mesenchymal stem cells.](lmaa049f0002){#F2}

Conclusion {#s9}
==========

During this unprecedented healthcare crisis, researchers and clinicians across the globe are working relentlessly to identify the best strategies and treatment for patients with COVID-19. Although MSCs are a potentially promising therapy, they are still in the early stages of development for COVID-19 treatment. Further data from ongoing clinical trials across the world will help clarify their potential utility in battling the COVID-19 pandemic. **LM**

The article does not contain the participation of any human being or animal. All authors have seen the article and agree to the content and data. All the authors played a significant role in the article.
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:   U.S. Food and Drug Administration

NK cells

:   natural killer cells

IL

:   interleukin

TNF

:   tumor necrosis factor

ARDS

:   acute respiratory distress syndrome

ICU

:   intensive care unit

ACE-2
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:   computed tomography; PSI, patient safety indicators

MSCs

:   mesenchymal stem cells
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